Business
Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility - Endpoints News
What the report says
Novo Nordisk stops two more ziltivekimab heart trials, HERMES and ATHENA, after July's ZEUS failure casts doubt on IL-6 inhibition in heart disease.
Loading debate for this article…
Other publishers covering this story
No additional verified coverage is currently clustered with this report.
Related reporting
Drought effect on regional milk industry as Kenya turns to UgandaThe Independent Uganda
The 25 years we were never taught to liveThe Observer
Kenya halts deportations of foreign small-scale traders - monitor.co.ugDaily Monitor
Why Uganda wants private money to help transform farmingThe Observer
Tension as Koboko, Yumbe dispute Araga boundary - monitor.co.ugDaily Monitor
KCCA’s revenue bet: Help businesses survive, then tax their growth - Daily MonitorDaily Monitor